Results 61 to 70 of about 8,113 (209)
Pulmonary Circulation, Volume 15, Issue 2, April 2025.ABSTRACT Pulmonary hypertension (PH) is defined hemodynamically as a mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, measured at right heart catheterization (RHC). Pulmonary arterial hypertension (PAH) is defined as a mPAP ≥ 20 mmHg with a pulmonary capillary wedge pressure (PCWP) or left ventricular end‐diastolic pressure (LVEDP) of ≤ 15 mmHg and a
Marshaleen Henriques King +5 more
wiley +1 more source
Successful Treatment with Bosentan of Lower Extremity Ulcers in a Scleroderma Patient
Case Reports in Medicine, 2013 Digital ulcers are a well-known problem in patients with systemic sclerosis. Lower extremity ulcers are less prevalent but are also a challenging and underestimated complication of the disease causing important pain and morbidity.
Alix Naert, Petra De Haes
doaj +1 more source
Effect of bosentan on intimal hyperplasia of carotid artery anastomoses in rabbits
Türk Kardiyoloji Derneği Arşivi, 2014 Objectives: We investigated the effect of bosentan on intimal hyperplasia of carotid artery anastomoses in rabbits. Study design: Eighteen New Zealand male rabbits were randomized into two groups, as drug (Group B) and non-drug (Group A).
Artan Jahollari +7 more
doaj +1 more source
Review of bosentan in the management of pulmonary arterial hypertension
Vascular Health and Risk Management, 2008 Eli Gabbay1, John Fraser2, Keith McNeil31Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, Western Australia, Australia; 2Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside ...
Eli Gabbay, John Fraser, Keith McNeil
doaj
Canadian Respiratory Journal, 2006 BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease.
Reda Ibrahim +2 more
doaj +1 more source
Respiratory Research, 2011 Background Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations.
Szema Anthony M +5 more
doaj +1 more source
Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan
BMC Cardiovascular Disorders, 2012 Background This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients.
De Haro Joaquin +4 more
doaj +1 more source
An Atypical Presentation of Liver Enzyme Elevation Resulting from Bosentan Use
Canadian Respiratory Journal, 2009 Hepatocellular enzyme elevation is a known side effect of both bosentan and atorvastatin. However, a rise in liver enzyme level not characteristic of either agent individually may represent a reaction to their combination or an atypical reaction to ...
Kimberley Mulchey, Zoheir Bshouty
doaj +1 more source
The Safety and Effects of Bosentan in Patients with a Fontan Circulation
Congenital Heart Disease, 2012 Adult patients with a Fontan circulation tend to have diminished exercise capacity. The principal objective of this study was to investigate the safety of the endothelin receptor antagonist bosentan in Fontan patients, and, secondarily, to assess effects on cardiovascular performance, New York Heart Association functional classification (NYHA FC ...
Paul Clift +3 more
openaire +3 more sources
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A [PDF]
, 2000 Isabelle Binet +4 more
openalex +1 more source